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Abstract  
Objective: Usage of and views concerning alternative therapies in the DS community are not 
well documented. Some positive effects of green tea extracts (GTE) containing 
Epigallocathechin-3-gallate (EGCG) have been reported in individuals with DS and DS mouse 
models, but minimal improvements or detrimental effects of pure EGCG treatment have been 
reported in DS mouse models. Given the uncertainty about the effectiveness of these 
supplements, the goal of this study was to determine the relative prevalence of and attitudes 
about GTE/EGCG treatments among DS caregivers. 
Methods: An anonymous survey about attitudes and usage of GTE/EGCG in individuals with DS 
was completed by caregivers of these individuals. 
Results: GTE/EGCG treatment was provided by 18% of responding caregivers who were mostly 
younger, highly educated, and utilized scientific sources and other parents to influence their 
decision to use GTE/EGCG. Individuals with DS who received GTE/EGCG were characterized 
as less severely disabled. Most caregivers who did not give GTE/EGCG reported concerns about 
potential side effects and lack of effectiveness. Few caregivers consulted with medical providers 
about GTE/EGCG usage.  
Conclusions: These results demonstrate a need for communication between caregivers, medical 
providers, and scientists about potential benefits and risks for adverse effects of GTE, EGCG, 
and other nutritional supplements in individuals with DS. 
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1. Introduction  
Trisomy of human chromosome 21 (Hsa21), affecting approximately 1/800 live births 
(1), results in Down syndrome (DS) and alters cognitive, skeletal, and cardiac functions. 
Individuals with DS have lower intelligence quotients (IQ), though wide ranges of IQs are 
reported (2). Cognitive traits in individuals with DS have been refractory to conventional 
therapeutics and may worsen with age, often leading those caring for individuals with DS to 
consider alternative treatments including nutritional supplements (3-6). 
Increasing numbers of conventional and alternative therapies have been proposed, tested 
in preclinical DS mouse models, and progressed to clinical trials in individuals with DS (7). 
Some of these therapies have targeted specific neurotransmitter systems or aberrant neural 
pathways, based on their contribution to cognitive and behavioral phenotypes. Additional 
treatments have targeted genetic or molecular mechanisms thought to be altered by Ts21 (6, 7).  
DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A), a gene located 
on Hsa21, is a serine threonine kinase enzyme that appears to have a critical role during brain 
development, and three copies of DYRK1A has been hypothesized to lead to cognitive and 
skeletal deficits associated with Ts21 (8). Subtraction of one copy of Dyrk1a in otherwise 
trisomic DS mouse models improved cognitive, neurological, and skeletal deficits (9-12).  Thus, 
trisomic DYRK1A has been recognized as a rational target for therapeutic drug treatments (8, 
13).  
Epigallocatechin gallate (EGCG) is a putative treatment for DS phenotypes due to its 
ability to reduce DYRK1A activity in vitro (14), and reduce oxidative stress and mitochondrial 
energy deficits (6). EGCG is the major polyphenol (50-75%) found in green tea extracts (GTE) 
and is a candidate treatment to improve cognitive and developmental phenotypes associated with 
4 
 
DS. Treatment of mice with an extra copy of Dyrk1a with GTE improved performance on a task 
of learning and memory and improved neurological abnormalities (15-17). Administration of 
GTE containing EGCG in the Ts65Dn DS mouse model improved hippocampal dependent 
learning (18). [For a comprehensive review of these treatments see (19)]. These preclinical data 
in mice suggest that treatment with GTE with EGCG could correct some neurological deficits 
and improve hippocampal-dependent learning and memory in trisomic mice.  
Other studies have failed to confirm positive effects of EGCG in normalizing DS 
phenotypes, particularly preclinical experiments using pure EGCG treatment and assessing DS-
related neurological and skeletal deficits. Treatment of Ts65Dn mice with ~9 mg/kg/day EGCG 
improved several bone deficits, and some improvements were similar to those found in Ts65Dn 
mice with only two copies of Dyrk1a (12). A dosage of ~9 or 20mg/kg/day EGCG, however, did 
not improve cognitive defects in Ts65Dn mice (20). GTE supplements containing EGCG were 
detrimental to bone strength in Ts65Dn mice (21). Treatment with 50 mg/kg/day EGCG also did 
not improve DS-related cognitive deficits and worsened skeletal phenotypes in Ts65Dn mice 
(22).  
A phase-one type trial in 31 individuals with DS given GTE with ~9 mg/kg/day EGCG 
for 3 months found that individuals with DS receiving GTE showed improvement in memory 
and executive function (18). In a second trial, 84 individuals with DS received GTE with 8-12 
mg/kg/day EGCG or placebo for 12 months while participating in additional cognitive training. 
Individuals who received GTE exhibited some improvements in visual recognition, executive 
function, and adaptive behavior (23). We hypothesized that these reports of modest 
improvements in individuals with DS after treatment with GTE would spur therapeutic usage of 
GTE and EGCG supplements. 
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In a survey examining the use of dietary supplements in individuals with DS, 
approximately half of the individuals with DS were receiving at least one supplement and 8.7% 
indicated that they used GTE (3). Because of published reports of positive, null, and negative 
effects in preclinical studies of GTE and EGCG, and trials examining the effects of GTE in 
individuals with DS, we wanted to characterize the DS community’s knowledge, perception, and 
experience with GTE and quantify the administration of GTE/EGCG in individuals with DS.  
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2. Materials and methods 
 
A Qualtrics-based survey, “Attitudes about and usage of Epigallocatechin-3-gallate 
(EGCG) as a therapy in individuals with Down syndrome” was designed by authors JRW, RJR, 
CMD, RL and CRG, reviewed and modified to include suggestions by a DS-Connect 
(https://dsconnect.nih.gov/) review panel, and given exempt status by the Indiana University 
Institutional Review Board as protocol number 1710755582. The survey was disseminated via 
DS-Connect and through various DS clinics and associations across the United States via an 
email to prospective respondents. The email described the survey and the eligibility criteria as a 
parent or caregiver of an individual with DS and asked them to complete the survey. The survey 
remained open for a 6-month period from January-June 2018.  
Based on their response to the first question, “Have you ever used EGCG or green tea 
extract to treat your child?”, participants were divided into separate tracks. According to their 
answer to the first question, caregivers were asked questions assessing their attitudes toward and 
extent of GTE/EGCG usage. Individuals from all tracks were asked demographic questions 
about the individual with DS and the caregiver, education levels of the individual with DS and 
the caregiver, therapy, medication, and perceived level of intellectual ability. Caregivers who had 
knowledge of GTE/EGCG were asked about how they learned about the supplement and their 
interactions with other individuals with DS. Those who had or were giving GTE/EGCG were 
asked questions about the kind of supplement used, supplement administration, and expectations 
for improvement.  
This study utilized a cross-sectional design with a single time point, during which 
participants completed our survey.  Descriptive statistics (e.g., frequencies, means, and standard 
deviations) were used to analyze the responses in order to capture the distribution of responses 
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for each question. A one-way analysis of variance (ANOVA), which tests whether a continuous 
dependent variable (e.g., age) varies between conditions, was performed to examine whether the 
age of caregivers significantly differed across GTE/EGCG usage groups. Finally, Chi-Square 
tests of independence were performed to test whether there were significant relationships 
between categorical variables. In particular, we examined relationships between: caregiver 
education level and learning about GTE/EGCG from other caregivers, classroom environment of 
individual with DS and GTE/EGCG usage, and child's level of intellectual disability and 
GTE/EGCG usage.  
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3. Results 
 
3.1 Demographic Information of the Entire Sample (N=348) 
A total of 348 caregivers of individuals with DS responded to the survey and answered 
the first question “Have you ever used EGCG or green tea extract to treat your child?” in one of 
four ways: A. Yes, I currently give EGCG to my child (N=47, 13.5%); B. Yes, but I stopped 
giving EGCG to my child (N=17, 4.9%); C. No, I have never given EGCG to my child, but I am 
aware of its use (N=71, 20.4%); or D. I don’t know anything about EGCG and I have never 
given it to my child (N=213, 61.2%). Of all respondents, 18.4% reported giving GTE or EGCG 
to their dependent with DS currently or in the past. Demographics of caregivers are found in 
Table 1. The average age of the caregivers was significantly different among GTE/EGCG usage 
groups, F(3, 315)=11.255, p<0.001. Caregivers who reported not knowing about and not giving 
GTE/EGCG to their child were significantly older than those who reported they were aware of 
its use but had never given it to their child (p<0.001 , d=0.66, Mean Difference=6.54, SE=1.47, 
95% CI [2.74, 10.34]), and those who reported currently giving GTE/EGCG to their child, 
(p<0.001, d=0.81, Mean Difference=7.64, SE=1.79, 95% CI [3.01, 12.26]). A significant 
relationship was observed between caregiver education and learning about GTE/EGCG from 
other caregivers; the higher the education level of the caregiver, the less likely they were to hear 
about GTE or EGCG usage from other caregivers [χ2(4, N=115)=10.32, p=0.035].  
The characteristics of individuals with DS as provided by their caregivers are found in 
Table 2. There was a significant relationship between classroom environment of the individual 
with DS and use of GTE/EGCG, [χ2(6, N=112)=14.04, p=0.029]; individuals with DS who were 
given GTE or EGCG were more likely to be in a mainstreamed classroom. There was also a non-
significant trend in the relationship between the child’s level of intellectual disability and GTE or 
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EGCG usage, [χ2(4, N=113)=8.39, p=0.078]; individuals with DS who received GTE or EGCG 
were reported as having a milder disability than individuals with DS with a caretaker who 
responded that they did not know about GTE/EGCG.  
3.2 Current GTE/EGCG Users 
At the time the survey was given, 47 of the respondents reported administering GTE or 
EGCG to their child with DS. For these responses, the average age of these caregivers was 44.1 
(SD=7.7) years, and the child’s average age was 8.3 (SD=7.1) years (range: 8 months-28 years). 
The mean reported weight of the child was 27.4 kgs (SD=18.1), and the mean reported mg/day of 
EGCG given to the individual was 272 mg/day (SD=314.1; range: 0-1200mg). Of the 
respondents who reported both weight and mg/day, the mean dosage was 10 mg/kg/day EGCG.  
Respondents who currently administer GTE or EGCG heard about this nutritional 
supplement mostly through scientific publications (Fig. 1A). The majority (28/40) administered 
GTE/EGCG once a day, 9/40 twice a day, two people less frequently than every other day, and 
one person every other day. The majority (36/40) purchased the supplement online, and two 
respondents each reported buying in a supplement shop or a supermarket. The most common 
form of GTE or EGCG was capsule (22/40) followed by powder (17/40), and two reported using 
liquid (individuals chose multiple options in their response). Three people changed forms of the 
nutritional supplement during treatment. Information about brand usage is found in Supplemental 
Table 1. 
For individuals receiving GTE or EGCG at the time of the survey, the mean age that 
treatment began was 6.5 years (range: 0 months-27 years). Twenty-three people had been using 
GTE/EGCG for more than 1 year, 12 individuals between 6 months-1 year, 4 between 1 month-6 
months, and one person reported giving GTE/EGCG for less than a month. Three caregivers 
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perceived benefits from treatment within a few months, 8 within a month, 7 in ~2 weeks, while 
others reported seeing benefits as soon as a week (N=7) or a few days (N=3) (Fig. 1B). Many 
individuals reported that their expectations were met or somewhat met while giving GTE/EGCG 
(Fig. 1C) including improvements in cognition, learning, memory, DYRK1A and GABA 
inhibition, increased energy, and speech. Only one person reported a side effect that the 
supplement interfered with sleep.  
3.3 Previous users of GTE or EGCG 
Of the 17 individuals who used GTE/EGCG in the past, the mean age of the caregiver 
was 45.1 (SD=8.6) years, and the child’s mean age was 10.5 (SD=6.9) years (range: 3 years-26 
years). The child’s average weight during the time of administration was 27.4 kg (SD=21.9) and 
the self-reported dosage was 385.3 mg/day (SD=632.4; range: 1-2,000 mg/day). Of the 
respondents who gave both weight and dosage, 28 mg/kg/day EGCG was the average dose. The 
top responses for where they heard about GTE/EGCG were scientific studies, other parents and 
the internet (Fig. 2A). 
 The mean age at treatment of individuals with DS who received GTE or EGCG and 
subsequently stopped was 10.5 years (range: 6 months-22 years). The majority (11/12) 
administered GTE/EGCG once a day, with the most common form being powder (7/14), 
followed by capsule (6/14) and liquid (1/14). No one reported changing forms during the time of 
administration. Most reported using between 1-6 months (N=5) or only trying it once (N=4). 
Fewer reported using it for 6 months to a year (N=2) or less than a month (N=2). Only one 
person reported using for more than a year before stopping. Supplemental Table 1 contains the 
most commonly reported GTE or EGCG brands used for prior and current users. 
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 Ten individuals reported seeing no benefits in individuals with DS for whom they cared. 
Two people reported seeing improvement in verbal communication, and one was unsure if they 
saw improvement. Caregivers stopped giving GTE/EGCG because they saw no improvement 
(N=4), their child did not like the supplement (N=4), the child had an adverse reaction (N=2), or 
the supplement was too expensive (N=2). One person reported finding a better supplement. 
Three people from the “other” category reported the following reasons: their child’s physician 
did not recommend usage, wanting to limit the number of supplements the child received, and 
forgetting to reorder. 
 Six of ten people reported no side effects, and the other four reported side effects such as 
“over exertion, subsequent fatigue”, “turn pale, seemed out of it”, “lethargy”, and “possible 
increase in aggression”. Eight people reported that their expectations were not met, one person 
reported their expectations were somewhat met, and one reported their expectations were met. 
Caregivers aware of EGCG but have never used it  
The average age of the caregiver in the group who heard of GTE or EGCG but not used it 
was 45.2 (SD=8.9) years, and the child’s average age was 10.75 years (SD=9.5, range: 2 years-
48 years). In this group, most caregivers heard about GTE/EGCG from the internet (Fig. 2B). 
Potential side effects and lack of evidence for effectiveness were leading reasons for why 
caregivers chose not to administer GTE or EGCG (Fig. 2C). Other reasons for not using 
GTE/EGCG aggregated within the following five themes: considering it, uncertain of proper 
dosage/administration, cost, lacking knowledge, and concern over child’s health/potential 
interactions. 
3.4 Caregivers who didn’t know anything about EGCG 
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The average age of the 214 caregivers who knew nothing about EGCG was 51.8 
(SD=10.9) years, and the average age of the individual with DS from this group was 18 years 
(SD=11.8, range: 1 year-62 years).  
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4. Discussion 
The present study found 13.5% of the respondents currently, and 4.9% previously gave 
GTE/EGCG to individuals with DS. A recent study of dietary supplement use in individuals with 
DS reported 8.7% of respondents used GTE or EGCG (3). Differences between the two studies 
in the number of reported users of GTE and EGCG may be due to differences in sample sizes 
between the two studies; alternatively, the current study may have attracted more individuals 
who are using GTE/EGCG because of the specific mention of these supplements in the title of 
the survey. Because of the reports of trials with GTE/EGCG in individuals with DS, some 
respondents of the previous study (3) may not have considered EGCG a dietary supplement, but 
rather a verified treatment. In agreement with the previous study where parents learned about all 
supplements through a parent group or friend, many caregivers who currently or formerly 
administered GTE or EGCG in the present study reported learning about GTE/EGCG through a 
parent group or friend. Yet, of those currently or formerly using GTE or EGCG, many caregivers 
in this study identified as highly educated and reported reading scientific literature in addition to 
learning about GTE/EGCG from other parents. Current users were the only group to respond 
“no” more often than “yes” when asked if their child was taking any additional medications. 
Reported side effects, lack of improvement, and cost were among the main reasons for 
discontinuation of GTE/EGCG treatment. 
Treatment with green tea and EGCG has been linked to hepatotoxicity that likely depends 
on dosage, route of administration, and EGCG or other catechin content (24). Adverse effects 
were observed when high concentrations of GTE or EGCG were taken in a single dose, but 
fewer adverse effects when taken as a beverage (24, 25). Safe levels of EGCG in humans have 
been determined to be around 300 mg/day (24-26). Dosages from 150-800 mg/kg EGCG have 
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been linked to damage in the liver, kidney, thymus, spleen, and pancreas of EGCG in adults (24, 
25, 27). There is a high risk of hepatoxic interactions between dietary supplements and other 
drugs, and most individuals are unaware of such interactions (28).  
The results from this study found a wide range in EGCG dosage with a mean of 351 
mg/day and a range up to 2000 mg/day. A dosage of 300 mg/day or greater was reported by 
14/64 respondents who have used or are currently using EGCG. In comparison, the small human 
studies administered GTE with 9 mg/kg/day EGCG for 3 months to individuals from 14-19 years 
of age (18) and 8-12 mg/kg/day for 12 months to individuals from 16-34 years (23).  
Many respondents also reported that individuals with DS were taking additional 
medications that could interact with GTE/EGCG. Animal studies indicate that GTE/EGCG could 
increase the bioavailability of diltazem, verapamil, tamoxifen, simvastatin, 5-fluorouracil, and 
nicardipine and decrease bioavailability of quetiapine, sunitinib, clozapine, and nadolol (29). In 
humans, GTE was shown to interact with simvastatin, rosuvastatin, sildenafil, tacrolimus, 
warfarin and nadolol, depending on GTE dosage and human variability (30, 31). Also in humans, 
large amounts of GTE/EGCG may interfere with drugs like rosuvastatin that are substrates of 
organic anion transporting polypeptides (OATP), but this may also may differ according to 
treatment regimen and allelic differences in the OATP genes (29, 30). Some of the GTE/EGCG-
drug interactions may contribute to liver damage (29). One individual in the group who heard of 
GTE or EGCG but not used it reported using sildenafil. Caution should be exercised with 
individuals taking medications with supplemental GTE/EGCG. The age of the individuals and 
duration of the treatment in our survey varied from 0-27 years (M=6.5 years) and most 
individuals received GTE/EGCG for over a year. The majority of individuals who responded to 
our survey gave GTE/EGCG to individuals who were >10 years of age (57%) and 53% began 
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giving the supplement to individuals with DS between 1-10 years of age, with an additional 19% 
of individuals with DS receiving the supplement at less than a year of age. Forty-one percent of 
the caregivers who gave GTE/EGCG but had discontinued gave it to individuals with DS under 
the age of 10, and 29% of people who had discontinued administration of GTE/EGCG gave it to 
individuals with DS less than 12 months of age. No studies of GTE/EGCG have been done on 
humans less than 14 years of age, raising concerns about administration of GTE/EGCG to young 
individuals with DS without knowing any potential dangers of GTE/EGCG at a young age. 
There were also widely ranging amounts of EGCG in GTE utilized (Supplemental Table 
1). Only five individuals with DS who were currently receiving or had received GTE/EGCG 
used the brand (Life Extensions) used in the small treatment trials (18, 23). Because the contents 
of supplements are not highly regulated, each supplement may not contain the advertised amount 
of EGCG (21). Additionally, the content and number of other polyphenols found in different 
supplements may affect the bioavailability of EGCG (17, 32). Both of these factors may affect 
the therapeutic potential of the GTE. Because studies that have reported effectiveness of EGCG 
were administered as part of a GTE, other components of the GTE besides EGCG may provide 
the reported positive effect on phenotypes (19). While EGCG is often touted as the treatment to 
correct phenotypes associated with DS, studies examining EGCG alone have only been done in 
DS model mice. The separate effects of EGCG or other catechins found in GTE have not been 
tested in humans with DS.  
Besides phenotypes associated with DS, GTE/EGCG has been examined for 
effectiveness in other disorders including weight loss, eyestrain and blood pressure, prostate 
cancer, breast cancer, and cardiovascular disease (33-37). In most of these studies, there were 
treatment and control groups with particular designated outcomes.  A survey of unaffected 
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brothers of men with prostate cancer found that approximately one-third of the unaffected men 
were using a vitamin or supplement marketed for prevention of prostate cancer (33). About 6% 
of the men had used green tea, with ~5% currently using. Though not statistically significant, 
higher educational attainment and higher household income was associated with the use of 
prostrate related vitamins and supplements. Most individuals were using 2-3 supplements and 
23% received information about the supplement from a family member, 24% from a book or 
article, and 15% each from a physician other than an urologist or the internet or news report. 
Similar to our study, individuals were using supplements for a disorder based on information 
from articles or the internet and had a high educational attainment. Another survey study that 
examined complimentary medicine usage in cancer treatment found that 35% of individuals were 
using green tea (38). Eighty-six percent of their oncologists did not ask whether they were using 
complimentary medicines. Like our study, those that used complimentary medicine were 
significantly younger than those that did not and most did not consult with their health care 
provider. There were a number of potential significant interactions between anticancer agents 
and green tea.  
EGCG is just one of the supplements proposed to correct deficits in individuals with DS. 
Other supplements that are commonly given to individuals with DS include Nutrivene, 
antioxidants, vitamins, and fats/fatty acids; the average child with DS receives a range of 1-18 
supplements with an average of 3.3 per child (3). Interaction of these supplements with 
GTE/EGCG is not currently known, but given the drug-GTE/EGCG interactions, the potential 
for adverse results exists. The underreporting of supplement use to clinicians may exacerbate the 
risk of adverse interactions of GTE/EGCG and drugs or other supplements (31). 
5. Limitations 
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Limitations of this study include that the results were self-reported. These data may be 
biased by individuals who answered our study because they knew about or were using GTE or 
EGCG. However, ~60% of the individuals who responded to the survey reported not using 
GTE/EGCG. In addition, many individuals did not fully respond to all of the questions, and some 
reported brands of GTE without specifying the product name. Those who responded to the 
survey were likely connected to other caregivers of individuals with DS because the study was 
disseminated through DS-Connect and DS organizations. Individuals who were associated with 
DS-Connect were likely very interested in research, and that may have influenced the education 
status of the caregiver or the literature about GTE/EGCG they were able to access. The sample 
sizes for each group were largely uneven; prior users made up only ~5% of the responses. 
6. Conclusion  
A large majority of those who were aware of GTE/EGCG and had never used it indicated 
that they had found no evidence for the effectiveness or were concerned about potential side 
effects of GTE/EGCG. The majority of these individuals reported that they were familiar with 
EGCG through the internet. It may be that these individuals were aware of the positive and 
negative scientific studies about GTE/EGCG related to DS and elected not to administer the 
nutritional supplement for this reason. Relatively few of the caregivers who administered EGCG 
or had heard about it consulted a medical professional about its use. The DS community may 
benefit from further research regarding the efficacy and safety of GTE/EGCG, and discussing 
administration of this and all nutritional supplements with their medical providers. 
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Figure 1. Reports from caregivers currently giving EGCG to individuals with DS. (A) 
Descriptions of how caregivers learned about GTE/EGCG usage. (B) Reports of observed 
benefits of EGCG. “Other” responses included improvements in speech, energy, ability to focus, 
and “I don’t know”. (C) Description of level of satisfaction with the results observed after 
administering GTE/EGCG. N=40 in A and B, some caregivers provided multiple responses.  
 
Figure 2. Reports from caregivers who have previously used EGCG or were aware of EGCG but 
never used it. (A) Reports of how caregivers that previously administered EGCG found out about 
it. N=14, many respondents chose multiple sources. (B) Descriptions of how caregivers that were 
aware of EGCG, but never gave it to the individual with DS found out about EGCG. N=67, 
many respondents chose multiple sources. (C) Reasons for not using EGCG from caregivers that 
knew about EGCG but never gave it to an individual with DS. N=71, many caregivers gave 
multiple responses. 
 
 
 
 
Table 1: Demographics of caregiver respondents (N=348) 
 
  
Caregiver Demographic Information 
Variables I don’t know 
anything about 
EGCG 
N=213 
Never used 
EGCG but 
aware of use 
N=71 
I have used 
EGCG in the 
past 
N=17 
I currently use 
EGCG  
 
N=47 
N % N % N % N % 
Highest level of 
education 
 
High School Diploma or GED 
equivalent 
6 2.9 1 1.4 0 - 1 2.1 
Some college 28 13.1 6 8.5 1 5.9 3 6.4 
Bachelor’s degree 78 36.6 25 35.2 3 17.6 11 23.4 
Some graduate school 12 5.6 6 8.5 2 11.8 5 10.6 
Graduate degree 83 39 28 39.4 5 29.4 18 38.3 
No answer 6 2.8 5 7 6 35.3 9 19.1 
Age (years) 
 
18-30 0 - 0 - 0 - 2 4.3 
31-40 27 12.7 22 31 3 17.6 9 19.1 
41-50 72 33.8 26 36.6 6 35.3 20 42.6 
51-60 66 31 9 12.7 0 - 6 12.8 
61-70 32 15 4 5.6 1 5.9 1 2.1 
71-80 9 4.2 1 1.4 0 - 0 - 
No answer 7 3.3 9 12.7 7 41.2 9 19.1 
Interact with other 
DS families 
*only 3 tracks 
included 
Yes - - 66 93 12 70.6 38 80.9 
No - - 1 1.4 2 11.8 2 4.3 
No answer - - 4 5.6 3 17.6 7 14.9 
Involved in support 
group 
*only 3 tracks 
included 
Yes - - 59 83.1 12 70.6 35 74.5 
No - - 8 11.3 2 11.8 5 10.6 
No answer - - 4 5.6 3 17.6 7 14.9 
Gender 
 
Female 184 86.4 59 83.1 10 58.8 38 80.9 
Male 21 9.9 6 8.5 1 5.9 7 14.9 
Prefer not to identify 2 0.9 1 1.5 0 - 0 - 
No answer 6 2.8 5 7 6 35.3 2 4.3 
Ethnicity 
 
White or Caucasian 186 87.3 57 80.3 10 58.8 29 61.7 
Hispanic or Latino 8 3.8 4 5.6 0 - 4 8.5 
Black or African American 2 0.9 1 1.4 0 - 2 4.3 
Native American or American Indian 3 1.4 1 1.4 0 - 0 - 
Asian or Pacific Islander 5 2.3 1 1.4 1 5.9 1 2.1 
Other 2 0.9 2 2.8 0 - 2 4.3 
No answer 8 3.8 5 7 6 35.3 9 19.1 
Estimated yearly 
household income 
 
Less than $25,000 2 0.9 1 1.4 0 - 3 6.4 
$25,000- $50,000 16 7.5 2 2.8 0 - 3 6.4 
$50,000-$75,000 17 8 7 9.9 2 11.8 4 8.5 
$75,000-$100,000 34 16 12 16.9 2 11.8 3 6.4 
$100,000-$125,000 34 16 9 12.7 1 5.9 2 4.3 
More than $125,000 75 35.2 24 33.8 4 23.5 16 34 
Prefer not to identify 29 13.6 9 12.7 2 11.8 7 14.9 
No answer 6 2.8 7 9.9 6 35.3 9 19.1 
Country currently 
residing in 
 
In United States 201 94.4 64 90.1 11 64.7 25 53.2 
Outside of United States 1 0.5 2 2.8 0 - 9 19.1 
No answer 11 5.2 5 7 6 35.3 13 27.7 
Table 2: Demographics of individuals with DS from those that responded to the survey (N=348) 
 
 
 
Individual with DS Demographic Information 
Variables I don’t know 
anything about 
EGCG 
N=213 
Never used 
EGCG but aware 
of use 
N=71 
Used EGCG in the 
past 
N=17 
Currently use 
EGCG 
N=47 
N % N % N % N % 
Type of 
Down 
syndrome 
Trisomy 21 199 93.4 65 91.5 12 70.6 34 72.3 
Mosaic 4 1.9 0 - 0 - 1 2.1 
Translocation 4 1.9 1 1.4 0 - 1 2.1 
No answer 6 2.8 5 7 5 29.4 11 23.4 
Ethnicity White or Caucasian 181 85 56 78.9 10 58.8 28 59.6 
Hispanic or Latino 10 4.7 4 5.6 0 - 5 10.6 
Black or African American 3 1.4 1 1.4 0 - 2 4.3 
Native American or American Indian 1 0.5 1 1.4 0 - 0 - 
Asian or Pacific Islander 4 1.9 1 1.4 2 11.8 1 2.1 
Other 11 5.2 3 4.2 0 - 2 4.3 
No answer 3 1.4 5 7 5 29.4 9 19.1 
Educational 
environment 
Mainstreamed classroom or inclusive 64 30 41 57.7 3 17.6 15 31.9 
Special education center 39 18.3 4 5.6 2 11.8 3 6.4 
Other 35 16.4 9 12.7 4 23.5 5 10.6 
My child is not school aged 64 30 9 12.7 3 17.6 14 29.8 
No answer 11 5.2 8 11.3 5 29.4 10 21.3 
Level of 
intellectual 
disability 
Mild 71 33.3 27 38 9 52.9 21 44.7 
Moderate 117 54.9 35 49.3 2 11.8 16 34 
Severe 19 8.9 3 4.2 0 - 0 - 
No response 6 2.8 6 8.5 6 35.3 10 21.3 
Additional 
therapies 
received 
*individuals 
gave multiple 
responses 
Speech 134 62.9 53 74.6 9 52.9 28 59.6 
Occupational 99 46.5 47 66.2 6 35.3 22 46.8 
Life skills 53 24.9 5 7 2 11.8 3 6.4 
Physical 50 23.5 30 42.3 4 23.5 18 38.3 
Social 30 14.1 12 16.9 2 11.8 5 10.6 
Other 22 10.3 13 18.3 2 11.8 7 14.9 
No response 41 19.2 8 11.3 5 29.4 13 27.7 
Sex Male 117 54.9 36 50.7 9 52.9 17 36.1 
Female 91 42.7 30 42.3 3 17.6 20 42.6 
No response 5 2.3 5 7 5 29.4 10 21.3 
Additional 
medications 
Yes 138 64.8 40 56.3 10 58.8 17 36.2 
No 72 33.8 26 36.6 2 11.8 21 44.7 
No response 3 1.4 5 7 5 29.4 9 19.1 
Current age Less than 12 months 0 - 0 - 0 - 1 2.1 
1 year- 10 years 71 33.3 43 60.6 7  41.2 26 55.3 
11 years-20 years 68 31.9 16 22.5 4  23.5 9 19.1 
21 years- 30 years 34 16 2 2.8 1,  5.9 2 4.3 
31 years- 40 years 25 11.7 2 2.8 0 - 0 - 
41 years- 50 years 7    3.3 2 2.8 0 - 0 - 
51 years – 60 years 4 1.9 0 - 0 - 0 - 
61 years- 70 years 1 0.5 0 - 0 - 0 - 
No response 3 1.4 6 8.5 5  29.4 9 19.1 
Age at start of 
administration 
Less than 12 months - - - - 3 17.6 6 12.8 
1 year – 10 years - - - - 5  29.4 25 53.2 
11 years – 20 years - - - - 4  23.5 8 17 
21 years – 30 years - - - - 1 5.9 2  4.3 
31 years – 40 years - - - - 0 - 0 - 
No response     4  23.5 6  12.8 
Figure 1. 
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Supplemental Table 1: Commonly reported green tea extracts 
Commonly Reported Green Tea Extracts 
Name Number of 
reported 
users 
(prior and 
current) 
Polyphenol content Cost per 
capsule/mL 
Average 
reported 
mg/day 
Nutrivene* 9 *See below NA 9.5 
Nutrivene D 1 Does not contain EGCG $0.28 NA 
Nutrivene polyphenol 
support 
4 98% polyphenols (588mgs) 
and 45% EGCG (270mgs) per 
serving 
$0.50 19.3 
Swanson‚Äôs Ultra 
GreenSelect Green Tea 
Phytosome 
6 19-25% polyphenols (114-
150mgs), 13% EGCG (78mgs) 
$0.28 255 
Now Foods EGCG Green 
tea extract 
6 200mg EGCG (50%), 80% 
catechins 
$0.17 260 
Life Extension Mega Green 
Tea Extract (Decaf) 
4 98% polyphenols (45% 
EGCG- 326.25mgs) 
$0.23 712.5 
Teavigo 3 94% EGCG (141mg) per 1 
capsule 
$0.22 217 
Vitacost Green Tea Select 2 250mg EGCG (50%), 98% 
polyphenols (490 mgs), 80% 
catechins (400mgs) 
$0.6 150 
Elite Green Tea Phytosomal 
Extract  
2 13mg EGCG (40%), 20mg 
polyphenols (60%) 
$0.18 200 
Life Extension Megan 
Green Tea Extract 
(Caffeinated) 
1 98% polyphenols (45% 
EGCG- 326.25mgs) 
$0.23 200 
Solaray Double Strength 
Green Tea Capsules 
1 250mg EGCG (50%), 98% 
polyphenols (490 mgs), 80% 
catechins (400mgs) 
$0.28 500 
Nature’s Answer Super 
Green Tea  
1 100mg GTE: EGCG (50%), 
95% polyphenols, 80% 
catechins 
$0.24 NR 
Relentless Improvement 
Decaffeinated EGCG 
1 670mg EGCG per capsule for 
1340mg per serving, more than 
60% EGCG. Polyphenols 
standardized to 98%+. 
$0.30 409 
Average   $0.25 267 
Others reported: Kenko Organic Matcha Green Tea powder, Organic Matcha culinary grade green tea 
powder, “drink green tea”, Trader Joe’s Decaf Green Tea, Encha organic powder, “different supplements 
which were laboratory tested for their biological activity”, matcha powder 
*Indicates respondent only reported brand  
 
